35. Failure to normalize risk profile of spine fusion patients with coronary artery disease

BACKGROUND CONTEXT Vascular stenting is a common intervention for patients afflicted with coronary artery disease. For elective spine fusion patients with a history of coronary artery disease, a stent provides a less invasive surgical intervention allowing patients to move forward with spinal surgery. However, the impact of an initially less invasive cardiac intervention on outcomes of future surgical spine procedures has been understudied. PURPOSE Investigate effect of coronary stents on postoperative outcomes in an elective spine fusion cohort. STUDY DESIGN/SETTING Retrospective review of the PearlDiver database between the years 2006-2013. PATIENT SAMPLE A total of 726,061 elective spine fusion patients. OUTCOME MEASURES Comorbidity burden, 30-day and 90-day complications (myocardial infarction, pneumonia, sepsis, death, would complications, transfusions), length of stay. METHODS Elective spine fusion patients were isolated with ICD-9 and CPT procedures codes in the PearlDiver database. Patients were stratified by number of coronary stents: (1) 1-2 stents (ST12); (2) 3-4 stents (ST34); (3) no stents. Means comparison tests compared differences in demographics, diagnoses, comorbidities, 30-day and 90-day complication outcomes. Logistic regression assessed the odds of complication associated with coronary stents, controlling for levels fused, age, sex, and comorbidities (odds ratio [95% confidence interval]). Statistical significance was set p RESULTS A total of 726,061 elective spine fusion patients were isolated; 707,396 patients had no stent, 17,087 ST12 and 1,578 ST34. At BL, ST12 patients had higher rates of morbid obesity, chronic kidney disease, CHF, COPD, and diabetes mellitus compared to no stent and ST34 (all p CONCLUSIONS Cardiac stents failed to normalize risk profile of patients with coronary artery disease. Postoperatively at 90 days, elective spine fusion patients with 3 or more stents were significantly at risk of mortality compared to patients with fewer or no stents. FDA DEVICE/DRUG STATUS This abstract does not discuss or include any applicable devices or drugs.